Nucleation frequency and rate of actin filament elongation are inhibited by SMIFH2. A, Nucleation frequency was measured by counting the total nucleation events per filament in a 400 μm2 over a 100 s time period after SMIFH2 treatment. Total nucleation frequency was inhibited by SMIFH2 treatment in a dose-dependent manner. Significant decrease of nucleation frequency appeared at concentrations of SMIFH2 greater than 25 μm. n > 300 events from 30 cells of 15 hypocotyls per treatment, Student’s t test, ***P < 0.001. B, Nucleation frequency by origins was analyzed in the same way as described for nucleation frequency in A. Compared to mock treatment, nucleation frequency of filaments originating from the side of a filament or bundle decreased significantly after SMIFH2 treatment. However, nucleation frequency of filaments originating de novo or from ends changed slightly. n > 300 events from 30 cells of 15 hypocotyls per treatment, Student’s t test, ***P < 0.001, **P < 0.01, *P < 0.05, ND P ≥ 0.05. C, Box plots show the average filament elongation rate in epidermal cells from 5-d-old etiolated hypocotyls without or with a 5 min, 25 μm SMIFH2 treatment. The box spans first and third quartiles. The line inside the box shows median value. Bars on the top and bottom represent the maximum and minimum values. The red circles represent mean values for single filament elongation rate. Compared to the mock, the filament elongation rates were significantly slower with SMIFH2 treatment. n ≥ 100 single actin filaments per treatment, **P < 0.005, Student’s t test. D, The proportion of single actin filament elongation rates was altered with SMIFH2 treatment. Filament elongation rates were categorized into three populations: more than 2 μm/s, between 1 and 2 μm/s, and less than 1 μm/s, as described previously (). Compared to mock treatment, the percentage of filament elongation rates > 2 μm/s decreased with SMIFH2 treatment, whereas the percentage of filament elongation rates < 1 μm/s increased. n ≥ 100 single actin filaments per treatment, *P < 0.05, χ2 test.